Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Methamphetamine Serotonin Reuptake Inhibitor Action Pathway
Homo sapiens
Drug Action Pathway
Methamphetamine (metamfetamine) is a psychostimulant and sympathomimetic drug. It is mainly taken recreationally but can be taken for ADHD and exogenous obesity in the form of a drug called Desoxyn. Methamphetamine induces effects of euphoria and affects heart rate, body temperature, blood pressure, appetite, attention, mood, and responses associated with alertness or alarm conditions. The drug triggers mainly a fight or flight response in the body and brain.
Methamphetamine acts on the serotonin pathway both in the brain and in the gastrointestinal tract. More than 90% of serotonin is produced in gut cells. It is synthesized from Tryptophan which synthesizes 5-Hydroxy-L-tryptophan which synthesizes serotonin or 5-hydroxytryptamine. The mechanisms in which methamphetamine acts on serotonin are very similar to that of dopamine and norepinephrine in the presynaptic neuron. Methamphetamine inhibits Amine oxidase [flavin-containing] A which when uninhibited metabolizes serotonin into 5-Hydroxyindoleacetic acid. The inhibition of this causes serotonin to accumulate in the cytosol. Like norepinephrine the methods are less tested than for dopamine. The high concentration of serotonin in the synapse activates 5-hydroxytryptamine receptor 2A, 3A, and 3B on the postsynaptic neuron membrane. Activation of 5-hydroxytryptamine receptors in the gut causes the smooth muscles around intestines to contract which causes food to pass through the intestine more quickly. The faster food passes through, the less nutrients absorbed into the blood stream which would help with exogenous obesity. In the brain, the mechanisms of 5-hydroxytryptamine receptor activation is not well understood, but it has been found that there is an effect on mood, perception, cognition, which can possibly help with ADHD.
References
Methamphetamine Serotonin Reuptake Inhibitor Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Tellez R, Rocha L, Castillo C, Meneses A: Autoradiographic study of serotonin transporter during memory formation. Behav Brain Res. 2010 Sep 1;212(1):12-26. doi: 10.1016/j.bbr.2010.03.015. Epub 2010 Mar 11.
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98.
Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33.
Miller GM: The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011 Jan;116(2):164-76. doi: 10.1111/j.1471-4159.2010.07109.x.
Pubmed: 21073468
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings